S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q3 2021

Baker Bros Advisors

Period: Q3 2021 Β· Filed: 2021-11-15
View on SEC EDGAR β†—
AUM
$22.77B
Total portfolio value
Positions
122
Reported securities
Top Holding
SGEN
35.3% $8.03B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-11-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$8.03B35.26%β€”β€”
35.3%
ONCBeiGene, Ltd.$4.24B18.60%$363.00$297.65-18.0%
18.6%
INCYIncyte Corporation$2.20B9.67%$68.78$116.86+69.9%
9.7%
KODKodiak Sciences Inc.$1.41B6.19%$95.98$38.54-59.9%
6.2%
ASNDAscendis Pharma A/S$723.9M3.18%$159.39$274.50+72.2%
3.2%
ACADACADIA Pharmaceuticals Inc.$696.1M3.06%$16.61$25.97+56.4%
3.1%
BMRNBioMarin Pharmaceutical Inc.$589.0M2.59%$77.29$58.99-23.7%
2.6%
ARGXargenx SE$338.1M1.48%$302.00$939.68+211.2%
1.5%
PRLDPrelude Therapeutics Inc.$316.4M1.39%$31.25$4.91-84.3%
1.4%
NVTAQInvitae Corporation$280.7M1.23%β€”β€”
1.2%
MRTXMirati Therapeutics, Inc.$249.4M1.10%β€”β€”
1.1%
ABCLAbCellera Biologics Inc.$209.4M0.92%$20.04$8.11-59.5%
0.9%
IGMSIGM Biosciences, Inc.$207.5M0.91%β€”β€”
0.9%
BCRXBioCryst Pharmaceuticals, Inc.$182.7M0.80%$14.37$9.84-31.5%
0.8%
KYMRKymera Therapeutics, Inc.$140.1M0.62%$58.74$113.51+93.2%
0.6%
PACBPacific Biosciences of California, Inc.$139.1M0.61%$25.55$1.68-93.4%
0.6%
MDGLMadrigal Pharmaceuticals, Inc.$119.6M0.53%$79.79$528.10+561.9%
0.5%
LEGNLegend Biotech Corporation$119.5M0.52%$50.56$29.91-40.8%
0.5%
AMRNXXXXAmarin Corporation plc$111.5M0.49%β€”β€”
0.5%
IMCRImmunocore Holdings plc$93.4M0.41%$37.07$32.50-12.3%
0.4%
HRTXHeron Therapeutics, Inc.$86.9M0.38%$10.69$0.44-95.9%
0.4%
CERSCerus Corporation$83.5M0.37%$6.09$3.16-48.1%
0.4%
GBTGlobal Blood Therapeutics, Inc.$82.0M0.36%β€”β€”
0.4%
ALLKAllakos Inc.$74.4M0.33%β€”β€”
0.3%
NRIXNurix Therapeutics, Inc.$73.5M0.32%$29.96$23.97-20.0%
0.3%
DBVTDBV Technologies S.A.$71.6M0.31%$9.80$15.82+61.4%
0.3%
TILInstil Bio, Inc.$69.6M0.31%$357.50$7.73-97.8%
0.3%
VERVVerve Therapeutics, Inc.$66.6M0.29%β€”β€”
0.3%
VSTMXXXXVerastem, Inc.$66.2M0.29%β€”β€”
0.3%
HZNPHorizon Therapeutics Public Ltd Co$65.6M0.29%β€”β€”
0.3%

Quarter-on-Quarter Activity

Q3 2021 vs. Q2 2021

New Positions (8)

TickerIssuerNotional
DICEDICE Therapeutics, Inc.$19.3M
SRZNSurrozen, Inc.$17.7M
TCRXTscan Therapeutics, Inc.$11.9M
TNGXTango Therapeutics, Inc.$9.7M
AMYTAmryt Pharma plc$6.2M
KURAKura Oncology, Inc.$5.7M
ATYRaTyr Pharma, Inc.$5.7M
CCXIChemoCentryx, Inc.$5.2M

Exited Positions (8)

TickerIssuerNotional
APLSApellis Pharmaceuticals, Inc.$143.6M
ADCTADC Therapeutics SA$34.5M
PTGXProtagonist Therapeutics, Inc.$20.4M
ISEEIVERIC bio, Inc.$8.9M
ASMBAssembly Biosciences, Inc.$8.2M
SPRYSilverback Therapeutics, Inc.$7.4M
CHMAChiasma, Inc.$6.7M
ORTXOrchard Therapeutics plc$5.2M

Increased (8)

TickerIssuerNotionalShares Ξ”
BLUEXXXXbluebird bio, Inc.$40.5M+1001.3%
TVTXTravere Therapeutics, Inc.$46.7M+991.3%
Apellis Pharmaceuticals, Inc.$29.5M+211.7%
CNTACentessa Pharmaceuticals plc$9.9M+181.8%
RLMDRelmada Therapeutics, Inc.$2.8M+162.4%
MGNXMacroGenics, Inc.$3.9M+120.5%
BMEABiomea Fusion, Inc.$1.7M+78.4%
KDNYChinook Therapeutics, Inc.$9.0M+76.1%

Trimmed (7)

TickerIssuerNotionalShares Ξ”
MREOMereo BioPharma Group plc$-7.1M-88.1%
BioMarin Pharmaceutical Inc.$-11.0M-70.0%
AUPHAurinia Pharmaceuticals Inc.$-3.0M-53.5%
NVAXNovavax, Inc.$-8.0M-24.3%
AMRNXXXXAmarin Corporation plc$-4.4M-17.4%
NVTAQInvitae Corporation$-65.0M-3.7%
OPTEYOpthea Limited$-0.0M-0.9%
← Back to Hedge Funds